How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication – Akebia Therapeutics (NASDAQ:AKBA), Fresenius Medical Care (NYSE:FMS)

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing noncommunicable disease in the United States. 37 million American adults have CKD and more than 600,000 have End-Stage Renal Disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive. In fact, more people die each year from this silent killer than from breast or prostate cancer.

Hyperphosphatemia (elevated levels of phosphorus in the blood) is a common complication of CKD, affecting more than 80% of dialysis patients.

Uncontrolled phosphorus levels often cause other complications, such as heart disease and bone fractures, increasing the risk of hospitalization by up to 38% and the risk of mortality by up to a staggering 102%. Although there are six Food and Drug Administration (FDA)-approved medications on the market to treat hyperphosphatemia, 75% of patients with hyperphosphatemia are unable to lower their phosphorus to target levels. Some of the products currently available include Auryxia, produced by Therapeutic Akebia AKBAand Velphoro, from Fresenius Medical Care AG & Co. FMS.

As such, it would appear that the drugs currently available on the market cannot fully address the needs of the patient population. A California company is looking to do its part to help change that.

Will your new pill help solve this growing problem?

Unicycive Therapeutics Inc. UNCY, a Los Altos, California company, is looking to develop a solution that is more effective than its competitors. The company is developing a patented drug called RenazorbTM which is less than 2 years away from possible FDA approval, which binds and removes phosphate in the gastrointestinal tract.

This new drug uses a proprietary nanoparticle technology that (if approved) Unicycive believes will more effectively reduce phosphorus to desired levels. RenazorbTM also offers greater comfort to patients because it is swallowed with water instead of having to be chewed.

recently unicycle official a survey of nephrologists (doctors who specialize in kidney health) and found that their top concerns in managing hyperphosphatemia in their patients was the need for fewer pills and better patient compliance.

Many people with hyperphosphatemia also have other comorbidities that require taking other pills, creating a large pill burden. This leads to 62% of patients reporting noncompliance – patients who refuse to take their medications because they are overwhelmed by the number and size of pills they need to take and their side effects.

The efficiency and smaller size of RenazorbTM pills can reduce the pill burden for these patients by 3-4 times. Consequently, nephrologists say they would prescribe RenazorbTM (once approved) to the 34% of their dialysis patients who require phosphate-binding therapy; this is a market-leading figure that indicates levels of physician confidence in the promise of this new drug.

Notably, Unicycive also recently signed an agreement with Lee’s Pharmaceutical (HK) Ltd.a subsidiary of Lee’s Pharmaceutical Holdings Ltd. LPCUFfor the exclusive distribution rights of RenazorbTM in China and other Asian markets.

The global market for hyperphosphatemia drugs stands at more than $2 billion (of which more than $1 billion is in the US market). It is expected to achieve a CAGR of 5.3% between 2021 and 2028. Unicycive believes this leaves the field open for a medicine that will bring real solutions to patients suffering from inappropriate and costly medicines for a persistent medical problem. all over the world.

“We were delighted to kick off our pivotal Renazorb(™) bioequivalence trial, which keeps us on track to complete the study by the end of the year and submit a new drug application in 2023,” said Shalaba Gupta, CEO of Unicycive. He also said that the agreement with Lee’s Pharmaceutical “underlines the potential of Renazorb (™) as the best phosphate binder in its class worldwide.”

To learn more about the company, visit their website

This post contains sponsored advertising content. This content is for informational purposes only and is not intended as investment advice.

featured photo by adobestock

Leave a Comment